FFO
BIOA

Fortitude Family Office’s BioAge Labs BIOA Stock Holding History

Fortitude Family Office’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27
Closed -$472 – 2393
2026
Q1 		$472 Sell
27
-93
-78% -$1.79K ﹤0.01% 1751
2025
Q4 		$1.59K Hold
120
– – ﹤0.01% 1270
2025
Q3 		$706 Buy
+120
New +$562 ﹤0.01% 1673

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Fortitude Family Office's BIOA Position: Q2 2026 in Review

Fortitude Family Office sold out of BioAge Labs (BIOA) in Q2 2026, closing a stake of 27 shares — an estimated $472 sold.

Fortitude Family Office first reported a position in BIOA in Q3 2025 and held it in 3 quarters. The position peaked at $1.59K in Q4 2025. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Fortitude Family Office reported no remaining BioAge Labs position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 27 BioAge Labs shares in Q2 2026, an estimated $472.
  • Fortitude Family Office first reported a position in BioAge Labs in Q3 2025 and held it in 3 quarters.
  • Fortitude Family Office's BioAge Labs position peaked at $1.59K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.